Latest Walgreens stock price forecast incorporates healthcare services expansion, which could unlock new revenue streams, driving valuations toward $25 by year-end based on current cash flow projections. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Walgreens chief executive officer Tim Wentworth highlighted what he called “continued improvement” in the company’s U.S. Healthcare segment, that includes Village Medical, Summit and CityMD. The U.S. healthcare segment, which reported $2.1 billion in third quarter sales, reported an operating loss of $64 million, which was much improved over the operating loss of $220 million in the year-ago quarter, “reflecting lower acquisition-related amortization and higher contributions from VillageMD risk-based business,” Walgreens said. Walgreens stock price forecast remains sensitive to healthcare policy changes, with regulatory clarity likely to lift sentiment, offering a pathway toward a $22.80 short-term price target.